BioSpace News Archive

CohBar, Inc., a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, reported its financial results for the third quarter ended September 30, 2021.

ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the third quarter and the nine-month period ended September 30, 2021.

Talis Biomedical Corporation, a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, announced the appointment of Brian Blaser to President, Chief Executive Officer and Director.

Icosavax, Inc., a biopharmaceutical company leveraging its innovative virus-like particle platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases, reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), today reported financial results and operating highlights for the third quarter and nine months ended September 30, 2021.

Fortress Biotech, Inc. announced financial results and recent corporate highlights for the third quarter ended September 30, 2021.

Graybug Vision, Inc. announced that Fred Guerard, PharmD, Chief Executive Officer of Graybug Vision, will participate in a pre-recorded fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference, which will be available on the conference website beginning at 10 a.m. ET / 7 a.m. PT on November 22, 2021.

Osmotica Pharmaceuticals plc, a specialty pharmaceutical company, announced business highlights and financial results for the three months ended September 30, 2021.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as non-alcoholic steatohepatitis, reported financial results for the third quarter ended September 30, 2021 and corporate highlights.

Rockwell Medical, Inc., a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, reported financial results and a business update for the three months ended September 30, 2021.